BioHealth News Archive
Successful Marketing and PR Strategies for Your Startup
Successful Marketing and PR Strategies for Your Startup PR and Marketing – What’s the difference? How do you establish your brand? Are there tips…
Read More
Healthy Funding: The Critical Role of Investing in NIH to Boost Health and Lower Costs | ITIF
NIH funding is critical to improving health outcomes and reducing the societal costs of illnesses. Congress should increase the NIH budget and then maintain…
Read More
Top 10 Immuno-Oncology Collaborations
A sampling of recent reports shows just how much immuno-oncology continues to grow. Last month, GrandView Research projected a more than doubling of the…
Read More
How Do You Start A Biotech Company?
To launch a company that might attract the investment you need to develop a promising new drug candidate or research tool you need to…
Read More
MedImmune spinout Viela Bio raising another $75M – Washington Business Journal
Viela Bio had raised $282 million when it launched at the end of February 2018. {iframe}https://www.bizjournals.com/washington/news/2019/03/22/medimmune-spinout-raising-another-75m-to-get-first.amp.html{/iframe}
Read More
Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases
HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced an extension of its partnership with Takeda Pharmaceutical Company Limited to discover and develop…
Read More
Paragon Bioservices Appoints New CTSO, Bolsters Leadership Ranks to Support Late-Stage Clinical and Commercial Biopharmaceutical Manufacturing – Paragon Bioservices, Inc.
Paragon Bioservices, the leading private equity-backed, biologics contract development and manufacturing organization (CDMO) announced today the appointment of Thomas VanCott, Ph.D., as Chief Technology and…
Read More
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax | Vaccines | News Channels
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and safety of AV7909 (anthrax…
Read More
Flagship Pioneering raises $824M in new fund – MedCity News
A life sciences-focused venture capital firm has raised more than $800 million for its latest fund. {iframe}https://medcitynews.com/2019/03/flagship-pioneering-raises-824m-in-new-fund/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=70996491&_hsenc=p2ANqtz-_DY41Wi4agZwnXpClpK4cbqQ25NHFajpbuwFHJqWI6FOaZT9ioU5F3vzEtr6h5qtDt6JmATgA9z29Qud3_m-GZjRRogQ&_hsmi=70996491{/iframe}
Read More
Interview: Viela Bio Eyes BLA for Lead Asset Only One Year After Launch | BioSpace
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug…
Read More
Johns Hopkins spinout Vixiar gets $1.5M for tablet-based cardiac measurement system | MobiHealthNews
Vixiar, a Johns Hopkins spinout marketing a tablet-based point of care system for assessing cardiac filling pressure, has raised $1.5 million in Series A…
Read More
GSK pancreatic cancer drug heads to phase 1 combo with Merck’s Keytruda after positive mouse trial | FierceBiotech
GlaxoSmithKline’s experimental drug GSK095 is designed to work in tandem with checkpoint inhibiting medicines in the hopes of empowering the immune system to launch a…
Read More
Emergent BioSolutions launches Phase 3 trial of anthrax vaccine – Homeland Preparedness News
Emergent BioSolutions said on Tuesday it will begin a Phase 3 trial of a new anthrax vaccine it is developing. The Phase 3 trial…
Read More
Researchers at Johns Hopkins offer new protocol to potentially cure sickle cell disease
There's new hope for patients who have blood diseases. Johns Hopkins Kimmel Cancer Center researchers say a new protocol offers the possibility of a…
Read More
What’s behind sky-high valuations of biopharma startups? – MedCity News
2018 was undoubtedly one of the most important years ever for biopharma, setting records for valuations and dealmaking. But a paper published in January…
Read More